Business ❯ Healthcare ❯ Pharmaceuticals

Market Competition

Eli Lilly Novo Nordisk Eli Lilly vs Novo Nordisk Biosimilars Pricing Strategies Generic Drugs Generics Product Launches Customer Acquisition Costs Immunotherapy Investor Relations Acquisition Talks Bidding Wars Industry Leaders Lundbeck and Avadel Bid Biotech Companies Antitrust Regulations Drug Pricing Sales Performance Drug Pipeline RSV Vaccine Zepbound Novo Nordisk vs Eli Lilly Obesity Drugs Drug Sales

Bristol Myers and Pfizer Offer Big Yields but Face Patent and Payout Risks

Investors must judge whether high headline yields hide payout stress from weak earnings after drug patents expire.

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Eli Lilly Lifts 2025 Guidance After Tirzepatide Fuels Blowout Quarter

LifeMD Faces Federal Securities Class Action as Firms Court Investors